After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

“It’s an exciting time to be in the field, but there’s so much to be considered.” If you have tried at least two antidepressant medications and they didn’t relieve your depression symptoms, you may ...

SPRAVATO ® has proven to be a transformational treatment option for many patients with TRD by reducing depression symptoms in as little as 24 hours and reducing the time to relapse for patients w ...

Johnson & Johnson's Spravato has been approved to treat a major ... based on individual needs," Mattingly added. "For the first time ever, we now have an option that gives patients freedom." ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Spravato was first approved back in 2019, but at that time, patients had to use it with an oral antidepressant. Now, it’s been approved to use on its own. It’s for adults with major depressive ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...